ALPHA 1-ANTITRYPSIN DEFICIENCY (AATD)
Clinical trials for ALPHA 1-ANTITRYPSIN DEFICIENCY (AATD) explained in plain language.
Never miss a new study
Get alerted when new ALPHA 1-ANTITRYPSIN DEFICIENCY (AATD) trials appear
Sign up with your email to follow new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY (AATD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
RNA editing drug WVE-006 enters first human safety trial
Disease control CompletedThis Phase 1 trial tested WVE-006, an RNA editing drug, in 47 healthy volunteers to see if it is safe and how the body processes it. The study is the first step toward a possible treatment for Alpha-1 antitrypsin deficiency, a genetic condition that can cause lung and liver disea…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY (AATD)
Phase: PHASE1 • Sponsor: Wave Life Sciences USA, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a smartphone breathing game help Alpha-1 patients breathe easier?
Symptom relief CompletedThis study tested a simple, home-based breathing technique called the Active Cycle of Breathing Technique (ACBT) with augmented reality support in 50 adults with Alpha-1 antitrypsin deficiency. Participants did the breathing exercises twice daily and walked at least 5000 steps pe…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY (AATD)
Sponsor: University of Parma • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC